These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
394 related articles for article (PubMed ID: 36709038)
1. Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC. Mok TSK; Lopes G; Cho BC; Kowalski DM; Kasahara K; Wu YL; de Castro G; Turna HZ; Cristescu R; Aurora-Garg D; Loboda A; Lunceford J; Kobie J; Ayers M; Pietanza MC; Piperdi B; Herbst RS Ann Oncol; 2023 Apr; 34(4):377-388. PubMed ID: 36709038 [TBL] [Abstract][Full Text] [Related]
2. Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC. Garassino MC; Gadgeel S; Novello S; Halmos B; Felip E; Speranza G; Hui R; Garon EB; Horinouchi H; Sugawara S; Rodriguez-Abreu D; Reck M; Cristescu R; Aurora-Garg D; Loboda A; Lunceford J; Kobie J; Ayers M; Piperdi B; Pietanza MC; Paz-Ares L JTO Clin Res Rep; 2023 Jan; 4(1):100431. PubMed ID: 36793385 [TBL] [Abstract][Full Text] [Related]
3. STK11 and KEAP1 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value among Hispanics (STRIKE registry-CLICaP). Cordeiro de Lima VC; Corassa M; Saldanha E; Freitas H; Arrieta O; Raez L; Samtani S; Ramos M; Rojas C; Burotto M; Chamorro DF; Recondo G; Ruiz-Patiño A; Más L; Zatarain-Barrón L; Mejía S; Nicolas Minata J; Martín C; Bautista Blaquier J; Motta Guerrero R; Aliaga-Macha C; Carracedo C; Ordóñez-Reyes C; Garcia-Robledo JE; Corrales L; Sotelo C; Ricaurte L; Santoyo N; Cuello M; Jaller E; Rodríguez J; Archila P; Bermudez M; Gamez T; Russo A; Viola L; Malapelle U; de Miguel Perez D; Rolfo C; Rosell R; Cardona AF Lung Cancer; 2022 Aug; 170():114-121. PubMed ID: 35753125 [TBL] [Abstract][Full Text] [Related]
4. Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC. Alessi JV; Elkrief A; Ricciuti B; Wang X; Cortellini A; Vaz VR; Lamberti G; Frias RL; Venkatraman D; Fulgenzi CAM; Pecci F; Recondo G; Di Federico A; Barrichello A; Park H; Nishino M; Hambelton GM; Egger JV; Ladanyi M; Digumarthy S; Johnson BE; Christiani DC; Lin X; Gainor JF; Lin JJ; Pinato DJ; Schoenfeld AJ; Awad MM J Thorac Oncol; 2023 Jun; 18(6):731-743. PubMed ID: 36775193 [TBL] [Abstract][Full Text] [Related]
5. Outcomes in patients treated with frontline immune checkpoint inhibition (ICI) for advanced NSCLC with KRAS mutations and STK11/KEAP1 comutations across PD-L1 levels. Sun L; Handorf EA; Zhou Y; Borghaei H; Aggarwal C; Bauman J Lung Cancer; 2024 Apr; 190():107510. PubMed ID: 38432028 [TBL] [Abstract][Full Text] [Related]
6. Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in West HJ; McCleland M; Cappuzzo F; Reck M; Mok TS; Jotte RM; Nishio M; Kim E; Morris S; Zou W; Shames D; Das Thakur M; Shankar G; Socinski MA J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35190375 [TBL] [Abstract][Full Text] [Related]
7. Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma. Shitara K; Özgüroğlu M; Bang YJ; Di Bartolomeo M; Mandalà M; Ryu MH; Caglevic C; Chung HC; Muro K; Van Cutsem E; Kobie J; Cristescu R; Aurora-Garg D; Lu J; Shih CS; Adelberg D; Cao ZA; Fuchs CS Ann Oncol; 2021 Sep; 32(9):1127-1136. PubMed ID: 34082019 [TBL] [Abstract][Full Text] [Related]
8. A Multicenter Retrospective Chart Review of Clinical Outcomes Among Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer. Iams WT; Balbach ML; Phillips S; Sacher A; Bestvina C; Velcheti V; Wang X; Marmarelis ME; Sethakorn N; Leal T; Sackstein PE; Kim C; Robinson MA; Mehta K; Hsu R; Nieva J; Patil T; Camidge DR Clin Lung Cancer; 2023 May; 24(3):228-234. PubMed ID: 36841727 [TBL] [Abstract][Full Text] [Related]
9. Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data. Dudnik E; Moskovitz M; Rottenberg Y; Lobachov A; Mandelboim R; Shochat T; Urban D; Wollner M; Nechushtan H; Rotem O; Zer A; Daher S; Bar J; Oncoimmunology; 2021 Jan; 10(1):1865653. PubMed ID: 33552685 [TBL] [Abstract][Full Text] [Related]
10. The prognostic impact of KRAS, TP53, STK11 and KEAP1 mutations and their influence on the NLR in NSCLC patients treated with immunotherapy. Proulx-Rocray F; Routy B; Nassabein R; Belkaid W; Tran-Thanh D; Malo J; Tonneau M; Ouarzadi OE; Florescu M; Tehfe M; Blais N Cancer Treat Res Commun; 2023; 37():100767. PubMed ID: 37832364 [TBL] [Abstract][Full Text] [Related]
17. Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials. Borghaei H; Langer CJ; Paz-Ares L; Rodríguez-Abreu D; Halmos B; Garassino MC; Houghton B; Kurata T; Cheng Y; Lin J; Pietanza MC; Piperdi B; Gadgeel SM Cancer; 2020 Nov; 126(22):4867-4877. PubMed ID: 32914866 [TBL] [Abstract][Full Text] [Related]
18. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer. Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176 [TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies. Nosaki K; Saka H; Hosomi Y; Baas P; de Castro G; Reck M; Wu YL; Brahmer JR; Felip E; Sawada T; Noguchi K; Han SR; Piperdi B; Kush DA; Lopes G Lung Cancer; 2019 Sep; 135():188-195. PubMed ID: 31446994 [TBL] [Abstract][Full Text] [Related]
20. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer. Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]